DaVita Beat Q2, Yet the Stock Fell-Why 20%-45% Upside Still Looks Plausible

DaVita beat Q2 estimates, but the market focused on risk

DaVita reported Q2 EPS of $4.02 versus a $3.88 estimate and also beat revenue expectations. Even so, the stock fell 6.68% after the release. Instead of rewarding the beat, the market seemed more focused on what could pressure earnings next.

That reaction fits DaVita's risk profile. With roughly two-thirds of U.S. sales coming from Medicare, investors are naturally more sensitive to reimbursement changes and payer-mix shifts than they are to one clean quarter.

The divide is straightforward: - Bulls see a dominant dialysis operator that can absorb policy friction. - Bears see a mature franchise whose future earnings still look too tied to government payment decisions.

For now, the bears clearly had more influence after earnings.

Guidance held, which matters more than the headline beat

The more constructive signal was that DaVita reconfirmed full-year adjusted operating income and EPS guidance. It also produced $256 million of second-quarter free cash flow and posted positive IKC adjusted operating income. Those figures do not erase Medicare risk, but they do support the case that the core business is still generating durable economics.

If management keeps that outlook intact, the current fear premium could compress.

The quarter had real operating traction

Core volumes, income, and cash flow stayed solid

DaVita posted $579 million of adjusted operating income, $256 million of free cash flow, and U.S. dialysis treatment volume growth of 56 basis points year over year. That combination matters because it shows both demand and conversion into cash, not just a cosmetic top-line beat.

The sequential cost mix also improved. Revenue per treatment fell by about $2, while patient care cost per treatment fell by about $3. When cost declines outpace revenue declines, margin pressure eases.

Other parts of the business also contributed

This was not only a story about U.S. dialysis and Medicare sensitivity. DaVita's international segment generated $25 million of adjusted operating income, and IKC produced positive $40 million of adjusted operating income. Those results suggest the quarter was supported by more than one operating vertical.

One caution is still worth noting. G&A costs rose by $11 million sequentially, and the financial impact of expanded HD technology is not expected to be significant until 2028. So the quarter looked operationally sound, but not like an immediate upside sprint.

Analyst targets still suggest meaningful upside

The post-earnings selloff did more than spook some holders; it changed the market's reference point. After the stock fell 6.68% despite a beat, investors began anchoring to that ugly close rather than to the fact that DaVita also reconfirmed full-year adjusted operating income and EPS guidance. With about two-thirds of U.S. sales coming from Medicare, fear is driving the debate more than the quarter's positives.

The rerating case is mainly about targets, not speculation

The recent analyst spread shows how divided sentiment still is. TD Cowen and Barclays recently set targets of $220 and $224, while Truist and UBS are still at $250 and $270. From there, the upside case is easy to map:

• Around $220 to $224: roughly 20% to 22% upside from recent levels.
• Toward $250 to $270: up to about 45% to 47% upside.

That does not require a dramatic change in fundamentals. It mainly requires less anchoring to the earnings-day drop and more acceptance of targets already far above the current share price.

Bulls can also point to Berkshire Hathaway's backing, with approximately 45% of DaVita owned by Berkshire Hathaway, as a sign of stability. Bears will still emphasize reimbursement pressure and recent insider selling. The key point is that the bullish case does not depend on a new story; it depends on the market valuing an existing business less pessimistically.

What would trigger the rerating?

The next real test is close: the next earnings call is scheduled for Oct. 28, 2026. Investors will be watching for three things:

• Guidance remains intact.
• U.S. treatment volumes stay positive.
• Management reinforces that the business can continue converting volume into cash even with Medicare exposure.

If those checkpoints hold, the stock has a plausible path to reprice toward the higher end of the current analyst range.